The failing heart has an increased metabolic demand and at the same time suffers from impaired energy efficiency, which is a detrimental combination. Therefore, therapies targeting the energy-deprived failing heart and rewiring cardiac metabolism are of great potential, but are lacking in daily clinical practice. Metabolic impairment in heart failure patients has been well characterized for patients with reduced ejection fraction, and is coming of age in patients with 'preserved' ejection fraction. Targeting cardiomyocyte metabolism in heart failure could complement current heart failure treatments that do improve cardiovascular haemodynamics, but not the energetic status of the heart. In this review, we discuss the hallmarks of normal card...
AbstractHeart failure is a major cause of morbidity and mortality in the world. Cardiac energy metab...
Both heart failure with reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpE...
Although neurohumoral antagonism has successfully reduced heart failure morbidity and mortality, the...
The failing heart has an increased metabolic demand and at the same time suffers from impaired energ...
It is unknown why heart failure progresses even when patients are treated with the best therapy avai...
The incidence and prevalence of heart failure have increased significantly over the past few decades...
Energy substrate metabolism and contractile function are tightly coupled in the heart. Within this f...
It is unknown why heart failure progresses even when patients are treated with the best therapy avai...
Heart failure (HF) currently affects more than 37 million people globally and is rising in prevalenc...
Despite advances in treatment, chronic heart failure is still associated with significant morbidity ...
Objectives. We will review current concepts regarding bioenergetic decline in heart failure (HF). In...
Despite significant therapeutic advances in heart failure (HF) therapy, the morbidity and mortality ...
The morbidity and mortality of coronary heart disease and of heart failure remain unacceptably high ...
Despite significant therapeutic advances in heart failure (HF) therapy, the morbidity and mortality ...
AbstractThe heart is responsible for pumping blood throughout the blood vessels to the periphery by ...
AbstractHeart failure is a major cause of morbidity and mortality in the world. Cardiac energy metab...
Both heart failure with reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpE...
Although neurohumoral antagonism has successfully reduced heart failure morbidity and mortality, the...
The failing heart has an increased metabolic demand and at the same time suffers from impaired energ...
It is unknown why heart failure progresses even when patients are treated with the best therapy avai...
The incidence and prevalence of heart failure have increased significantly over the past few decades...
Energy substrate metabolism and contractile function are tightly coupled in the heart. Within this f...
It is unknown why heart failure progresses even when patients are treated with the best therapy avai...
Heart failure (HF) currently affects more than 37 million people globally and is rising in prevalenc...
Despite advances in treatment, chronic heart failure is still associated with significant morbidity ...
Objectives. We will review current concepts regarding bioenergetic decline in heart failure (HF). In...
Despite significant therapeutic advances in heart failure (HF) therapy, the morbidity and mortality ...
The morbidity and mortality of coronary heart disease and of heart failure remain unacceptably high ...
Despite significant therapeutic advances in heart failure (HF) therapy, the morbidity and mortality ...
AbstractThe heart is responsible for pumping blood throughout the blood vessels to the periphery by ...
AbstractHeart failure is a major cause of morbidity and mortality in the world. Cardiac energy metab...
Both heart failure with reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpE...
Although neurohumoral antagonism has successfully reduced heart failure morbidity and mortality, the...